Liminatus Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-3.55	-3.55	-4.98	-2.93
Asset Writedown & Restructuring Costs	-	-	-	0.9
Change in Accounts Payable	-0.01	-0.01	0.43	0.09
Change in Other Net Operating Assets	2.11	2.11	1.21	1.07
Operating Cash Flow	-1.45	-1.45	-3.35	-0.87
Investing Cash Flow	-2.85	-2.85	-0.82	-
Short-Term Debt Issued	-	3.92	3.41	9.44
Total Debt Issued	3.92	3.92	3.41	9.44
Short-Term Debt Repaid	-	-	-3.86	-7.03
Total Debt Repaid	-	-	-3.86	-7.03
Net Debt Issued (Repaid)	3.92	3.92	-0.45	2.42
Issuance of Common Stock	-	-	-	4.2
Repurchase of Common Stock	-	-	-	-0.7
Financing Cash Flow	3.92	3.92	-0.45	5.92
Net Cash Flow	-0.38	-0.38	-4.61	5.05
Cash Interest Paid	-	-	-	0.5
Levered Free Cash Flow	-	-2.92	-2.3	-
Unlevered Free Cash Flow	-	-2.71	-2.19	-
Change in Working Capital	2.1	2.1	1.64	1.16

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q